Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Patient Safety Solutions to Prevent up to 70% of Adverse Events

Frost & Sullivan
Posted on: 24 Feb 18

SANTA CLARA, Calif., Feb. 22, 2018 /PRNewswire/ -- Frost & Sullivan's recent analysis, Patient Safety in Healthcare, Forecast to 2022, assesses the 30 most pressing safety adverse events affecting patients, caregivers, and healthcare organizations across the globe. Cumulatively, these adverse episodes affected an estimated 91.8 million patient admissions across the US and Western Europe resulting in around 1.95 million deaths at an average mortality of 2.1 percent and a significantly higher morbidity. The study also covers innovative and promising solutions, future market potential, convergence of new technologies, key market participants, competitive landscape, and investment trends.

In the next four years, adverse patient safety events in the United States and Western Europe such as healthcare associated infections (HAIs), sepsis, medication safety, pressure ulcers, diagnostic errors, antibiotic resistance and hand hygiene non-compliance will drive an estimated healthcare cost burden of $383.7 billion. While some adverse events, such as medication safety and hand hygiene non-compliance, are relatively well addressed by current industry solutions, under-penetrated areas such as antibiotic resistance, pressure ulcers, sepsis and unnecessary ED (emergency department) admissions will be the high opportunity growth areas for future.

For further information on this analysis, please visit: http://frost.ly/262.

Further trends driving growth in the patient safety market include:

A move to value-based, quality-driven reimbursement models;

Advancements in medical, surgical, and patient care technologies;

Integration between med-tech and digital health technologies such as data analytics, remote monitoring, and surveillance;

Data interoperability and enhanced use of predictive analytics for outcomes improvement; and

Emerging use of newer technologies such as blockchain, artificial intelligence and wearables to limit patient safety violations.

"Up to 17 percent of all hospitalizations are affected by one or more adverse events and around 15% of hospital expenditure is attributable to addressing them. The fact that 30 to 70 percent of these are potentially avoidable makes it imperative to prevent them from happening," said Anuj Agarwal, Transformational Healthcare Senior Research Analyst at Frost & Sullivan. "To reap growth opportunities, care providers and market participants should target their patient safety value proposition toward low-penetration areas with significant disruptive potential like antibiotic resistance, cybersecurity, avoidable ED admissions, pressure ulcers, and sepsis."

In the next four years, Frost & Sullivan predicts the following developments:

Patient safety transitioning from an ancillary to a core value proposition for care providers;

High adoption of patient and asset tracking as well as identification technologies;

Increased consolidation in the industry with large med-tech companies going for provision of targeted solutions for key unmet need areas;

Significant use of remote healthcare technologies such as Internet of Medical Things (IoMT) coupled with increasing healthcare data exchange, leading to disproportionate increase in cybersecurity risks such as  protected heath information (PHI) compromise and medical device/ implants data breach; and

Collaboration to develop guidance documents and draft policies for best practices on risk mitigation.

"The lack of clarity on available business models, fragmented and isolated vendor solutions addressing a specific set of issues in a particular segment, and disagreement on ideal patient safety solutions and implementation costs are major hurdles currently facing the market," observed Agarwal.

Patient Safety in Healthcare, Forecast to 2022 is part of Frost & Sullivan's Transformational Health Growth Partnership Service program.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.

Patient Safety in Healthcare, Forecast to 2022
K200_54

Contact:
Mariana Fernandez
Corporate Communications – North America
P: +1 (210) 348 1012
E: Mariana.Fernandez@frost.com

http://ww2.frost.com
twitter: @FS_Healthcare  
LinkedIn: Transform Health

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 24/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.